Literature DB >> 8769611

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group.

S T Donta1, P Peduzzi, A S Cross, J Sadoff, C Haakenson, S J Cryz, C Kauffman, S Bradley, G Gafford, D Elliston, T R Beam, J F John, B Ribner, R Cantey, C H Welsh, R T Ellison, E J Young, R J Hamill, H Leaf, R M Schein, M Mulligan, C Johnson, E Abrutyn, J M Griffiss, D Slagle.   

Abstract

To determine if passive immunization could decrease the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to intensive care units of 16 Department of Veterans Affairs and Department of Defense hospitals were randomized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immunized with a 24-valent Klebsiella capsular polysaccharide plus an 8-valent P. aeruginosa O-polysaccharide-toxin A conjugate vaccine, or an albumin placebo. The overall incidence and severity of vaccine-specific Klebsiella plus Pseudomonas infections were not significantly different between the groups receiving albumin and IVIG. There was some evidence that IVIG may decrease the incidence (2.7% albumin vs. 1.2% IVIG) and severity (1.0% vs. 0.3%) of vaccine-specific Klebsiella infections, but these reductions were not statistically significant. The trial was stopped because it was statistically unlikely that IVIG would be protective against Pseudomonas infections at the dosage being used. Patients receiving IVIG had more adverse reactions (14.4% vs. 9.2%).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769611     DOI: 10.1093/infdis/174.3.537

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Authors:  Weihui Wu; Jin Huang; Biyan Duan; David C Traficante; Haeyeon Hong; Martina Risech; Stephen Lory; Gregory P Priebe
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

3.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

4.  IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.

Authors:  Gregory P Priebe; Rebecca L Walsh; Terra A Cederroth; Akinobu Kamei; Yamara S Coutinho-Sledge; Joanna B Goldberg; Gerald B Pier
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 5.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

Authors:  A P Bolger; S D Anker
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  Vaccine approaches for multidrug resistant Gram negative infections.

Authors:  Brian Campfield; Kong Chen; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2014-03-15       Impact factor: 7.486

Review 7.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

Review 8.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 9.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 10.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.